M&A / Deals Servier wagers $2.65bn on Edgewise muscular dystrophy drug PharmaphorumServier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.Rare DiseaseRead full story pharminent June 1, 2026 (Last updated: June 1, 2026) Pharmaphorum Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise’s muscular dystrophy business headed by sevasemten. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO: Summit reached with China lung data but new climb begins to prove global benefitNext: CordenPharma inks AmbioPharm buyout to continue peptide production expansion Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
